Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05509933 · ClinicalTrials.gov registry record · Phase 3
Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation
A Phase 3 study of Engraftment Syndrome, sponsored by Henry Ford Health System.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 110
- Enrollment target
- 1
- Study location
NCT05509933: Recruiting Phase 3 study of Engraftment Syndrome, sponsored by Henry Ford Health System.
NCT05509933 is a Phase 3 study of Engraftment Syndrome that is actively recruiting participants, run by Henry Ford Health System. The registered enrollment target is 110 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05509933, a Phase 3 study of Engraftment Syndrome, is actively recruiting participants, sponsored by Henry Ford Health System.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.
Primary Outcome
non infectious fever defined as fever without identified infection that occurs up to 3 days prior and 10 days after the day of engraftment in patients on budesonide prophylaxis compared to patients who will not receive prophylaxis
Conditions Studied
Interventions
- DRUG Budesonide
Study Locations (1)
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2022-11-09 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 3 |
What NCT05509933 shows while recruiting
NCT05509933 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Engraftment Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Budesonide is the first listed.
NCT05509933 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT05509933 about?
NCT05509933 is a clinical study titled "Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation". The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.
What is the current status of trial NCT05509933?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 110 participants. The study started on 2022-11-09. Estimated completion is 2026-12-30.
What conditions does trial NCT05509933 study?
This clinical trial studies the following conditions: Engraftment Syndrome.
What interventions are being tested in trial NCT05509933?
The interventions under investigation include: Budesonide (DRUG).
Who is sponsoring clinical trial NCT05509933?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05509933 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05509933's enrollment target sits among peer trials
110 1658th of 2000 higher than 337 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI